turofexorate isopropyl
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2007 (NCT00499629)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Bile acid receptor FXRAGONIST
NR1H4 agonist
A Ph1 trial was terminated in May due to pharmacokinetics issues, development stopped.
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)OC(=O)C1=CN(C(=O)c2ccc(F)c(F)c2)CC(C)(C)c2c1[nH]c1ccccc21- Mol. weight
- 438.47 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL454138 ↗
Also known as
- fxr-450
- fxr-450
- fxr-450
- fxr-450
- turofexorate isopropyl
- turofexorate isopropyl
- turofexorate isopropyl
- way-362450
- way-362450
- way-362450
- xl335
- xl-335
- xl-335
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00509756 | Phase 1 | Nov 1, 2007 | Pfizer, Wyeth |
| NCT00499629 | Phase 1 | Oct 1, 2007 | Pfizer, Wyeth |
Showing 2 of 2 trials
Page 1 / 1